Background. Hemodialysis increases markedly the serum levels of hepatocyte growth factor (HGF) so that regular dialysis treatment (RDT) mimics the regular administration of HGF as a drug. Therefore, we have studied the effects of dialysis-associated HGF production on the severity of liver damage caused by hepatitis C virus (HCV). Methods. Biochemical tests of liver function and liver biopsy were performed in 10 patients on RDT and in 11 patients without renal disease (WRD) converted to anti-HCV serum-positive test for the same time (48 +/- 4 months). The HGF serum concentration was measured by enzyme immunoassay. In patients on RDT, HGF was measured just before starting a dialysis session (T-0), at 15 and 240 minutes of dialysis (T-15 and T-240) and 24 hours later (T-24 hr) Results. Serum HGF was similar in WRD (average 0.17 ng/ml) as in RDT at T-0 (0.25 ng/ml). In RDT serum HGF increased markedly at T-15 and T-240 (5.51 and 2.67 ng/ml, respectively, P < 0.001 vs. WRD and T-0) and was still higher than baseline at T-24 hr (0.41 ng/ml, P < 0.05). Both grade of necroinflammatory activity and stage of fibrosis were significantly lower in RDT than in WRD (both, P < 0.001). The number of apoptotic hepatocytes was also significantly reduced in patients on RDT compared with patients WRD. Conclusion. These results show that HCV-related liver disease is more benign in patients on RDT. The phenomenon may depend on the marked and prolonged HGF release caused by dialysis.

Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor

GREGORINI, MARILENA;LIBETTA, CARMELO;
1999-01-01

Abstract

Background. Hemodialysis increases markedly the serum levels of hepatocyte growth factor (HGF) so that regular dialysis treatment (RDT) mimics the regular administration of HGF as a drug. Therefore, we have studied the effects of dialysis-associated HGF production on the severity of liver damage caused by hepatitis C virus (HCV). Methods. Biochemical tests of liver function and liver biopsy were performed in 10 patients on RDT and in 11 patients without renal disease (WRD) converted to anti-HCV serum-positive test for the same time (48 +/- 4 months). The HGF serum concentration was measured by enzyme immunoassay. In patients on RDT, HGF was measured just before starting a dialysis session (T-0), at 15 and 240 minutes of dialysis (T-15 and T-240) and 24 hours later (T-24 hr) Results. Serum HGF was similar in WRD (average 0.17 ng/ml) as in RDT at T-0 (0.25 ng/ml). In RDT serum HGF increased markedly at T-15 and T-240 (5.51 and 2.67 ng/ml, respectively, P < 0.001 vs. WRD and T-0) and was still higher than baseline at T-24 hr (0.41 ng/ml, P < 0.05). Both grade of necroinflammatory activity and stage of fibrosis were significantly lower in RDT than in WRD (both, P < 0.001). The number of apoptotic hepatocytes was also significantly reduced in patients on RDT compared with patients WRD. Conclusion. These results show that HCV-related liver disease is more benign in patients on RDT. The phenomenon may depend on the marked and prolonged HGF release caused by dialysis.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/450162
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 72
social impact